Money talks as Chengdu firms up hub credentials

By Yuan Shenggao | China Daily | Updated: 2023-08-04 09:53
Share
Share - WeChat
An overhead view of the Tianfu Software Park in the Chengdu Hi-Tech Industrial Development Zone. CHINA DAILY

GE subsidiary

In May, the precision medical industrialization base project of GE Healthcare China, a subsidiary of US conglomerate General Electric, was officially launched in Chengdu's Tianfu International Bio-Town. Its business covers four major sectors: medical imaging, ultrasound, life care and pharmaceutical diagnostics.

The GE China Innovation Center — the company's first global customer co-innovation center — was established in Chengdu in 2011, and over the past decade has become a significant platform for GE Healthcare China.

In October 2022, GE Healthcare signed a cooperation agreement with Chengdu Hi-Tech Industrial Development Zone, officially marking the landing of the precision medical industrialization base project.

The city also hosts GE Healthcare China's customer service remote command center to help promote innovation activities, particularly in central and western China.

In recent years, GE Healthcare has continuously increased its investment in Chengdu and intensified cooperation in medical technology innovation, high-end equipment manufacturing and the construction of modern service hubs, aiming to promote the localization of high-end nuclear medicine equipment and the integration of precision medicine industry chains and supply chains while supporting the Healthy Sichuan action plan.

Chengdu Tianfu International Bio-Town has attracted more than 300 projects with a total investment exceeding 120 billion yuan, and by continuously updating its technology innovation platform and comprehensive transformation service system, has introduced a total of 123 platforms with diverse functions.

It has formed a public service platform system that covers the entire cycle of the new drug development chain, including target validation, optimization of lead compounds, screening and evaluation of drug efficacy, preclinical efficacy-safety evaluation, pilot process research and clinical trials.

|<< Previous 1 2 3 4 Next   >>|
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US